🇺🇸 Glyceryl trinitrate 0.2 in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 3
Most-reported reactions
- Nasal Dryness — 1 report (33.33%)
- Pollakiuria — 1 report (33.33%)
- Rhinorrhoea — 1 report (33.33%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Glyceryl trinitrate 0.2 approved in United States?
Glyceryl trinitrate 0.2 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Glyceryl trinitrate 0.2 in United States?
Recep Tayyip Erdogan University is the originator. The local marketing authorisation holder may differ — check the official source linked above.